Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm

Next Previous
X
Search
Trial Profile

A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Venetoclax (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms DEC10-VEN

    • Most Recent Events

    • 04 Jun 2024 Results assessing safety and efficacy of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed or pts with relapsed/refractory acute myeloid leukemia , or high-risk myelodysplastic syndrome presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jan 2024 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2023 Results assessing transcriptomic and DNA methylation analyses on VEN/DEC pre- and post-treatment samples from AML patients participating in a prospective clinical trial of DEC10-VEN (NCT03404193), were assessing presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top